Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy. (Q64942268)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30026866%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

4 references

14 November 2020

4 December 2020

8 February 2021

17 October 2022

Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30026866%20AND%20SRC:MED&resulttype=core&format=json

biomedical investigative technique

13 April 2020

main subject

1 reference

19 September 2019

1 reference

15 December 2019

1 reference

14 November 2020

1 reference

4 December 2020

1 reference

8 February 2021

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30026866%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

Nick Devoogdt

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30026866%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

Karine Breckpot

series ordinal

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30026866%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

Geert Raes

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30026866%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

5

Marleen Keyaerts

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30026866%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

2

Quentin Lecocq

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30026866%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

publication date

7 June 2018

7 references

19 September 2019

15 December 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30026866%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

14 November 2020

4 December 2020

8 February 2021

17 October 2022

7 references

19 September 2019

15 December 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30026866%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

14 November 2020

4 December 2020

8 February 2021

17 October 2022

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30026866%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

issue

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30026866%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

page(s)

3559-3570

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30026866%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution-NonCommercial

13 April 2020

copyright license

6 references

19 September 2019

15 December 2019

14 November 2020

4 December 2020

8 February 2021

17 October 2022

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

1 reference

12 December 2020

Inhibitory B7-family molecules in the tumour microenvironment

1 reference

12 December 2020

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

1 reference

12 December 2020

Therapeutic antibodies: successes, limitations and hopes for the future

1 reference

12 December 2020

Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+.

1 reference

12 December 2020

Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

1 reference

12 December 2020

PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients.

1 reference

12 December 2020

Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer

1 reference

12 December 2020

The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors

1 reference

12 December 2020

Progressive upregulation of PD-1 in primary and metastatic melanomas associated with blunted TCR signaling in infiltrating T lymphocytes

1 reference

12 December 2020

Antibody therapy of cancer

1 reference

12 December 2020

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

1 reference

12 December 2020

Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer

1 reference

12 December 2020

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

12 December 2020

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

1 reference

12 December 2020

The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer.

1 reference

12 December 2020

Deciphering and reversing tumor immune suppression.

1 reference

12 December 2020

Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells

1 reference

12 December 2020

PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients

1 reference

12 December 2020

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

1 reference

12 December 2020

Nivolumab in previously untreated melanoma without BRAF mutation

1 reference

12 December 2020

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

1 reference

12 December 2020

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

1 reference

12 December 2020

The lungs at the frontlines of immunity

1 reference

12 December 2020

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

1 reference

12 December 2020

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

1 reference

12 December 2020

The future of immune checkpoint therapy

1 reference

12 December 2020

Immune checkpoint blockade: a common denominator approach to cancer therapy

1 reference

12 December 2020

Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies.

1 reference

12 December 2020

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

1 reference

12 December 2020

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

1 reference

12 December 2020

PD-1/PD-L1 inhibitors.

1 reference

12 December 2020

Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes

1 reference

12 December 2020

Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma.

1 reference

12 December 2020

Imaging, Biodistribution, and Dosimetry of Radionuclide-Labeled PD-L1 Antibody in an Immunocompetent Mouse Model of Breast Cancer

1 reference

12 December 2020

Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging

1 reference

12 December 2020

A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors

1 reference

12 December 2020

Cancer-Associated Myeloid Regulatory Cells

1 reference

12 December 2020

High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers

1 reference

12 December 2020

PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET.

1 reference

12 December 2020

Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab.

1 reference

12 December 2020

Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma.

1 reference

12 December 2020

PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?

1 reference

12 December 2020

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

1 reference

12 December 2020

Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging.

1 reference

12 December 2020

Rapid PD-L1 detection in tumors with PET using a highly specific peptide.

1 reference

12 December 2020

Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch

1 reference

12 December 2020

Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model

1 reference

12 December 2020

Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines

1 reference

12 December 2020

The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy

1 reference

12 December 2020

Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers

1 reference

12 December 2020

Imaging of Programmed Cell Death Ligand 1: Impact of Protein Concentration on Distribution of Anti-PD-L1 SPECT Agents in an Immunocompetent Murine Model of Melanoma.

1 reference

12 December 2020

In vivo Imaging of the Programmed Death Ligand 1 by (18)F Positron Emission Tomography

1 reference

12 December 2020

18F-FDG PET and CT Scans Detect New Imaging Patterns of Response and Progression in Patients with Hodgkin Lymphoma Treated by Anti-Programmed Death 1 Immune Checkpoint Inhibitor.

1 reference

12 December 2020

The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC.

1 reference

12 December 2020

Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model

1 reference

12 December 2020

Corrigendum to "Rapid PD-L1 detection in tumors with PET using a highly specific peptide" [Biochemical and Biophysical Research Communications 483/1 (2017) 258-263].

1 reference

12 December 2020

Radiosynthesis and preclinical PET evaluation of 89Zr-nivolumab (BMS-936558) in healthy non-human primates.

1 reference

12 December 2020

Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma.

1 reference

12 December 2020

(89)Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer.

1 reference

12 December 2020

18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start.

1 reference

12 December 2020

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome.

1 reference

12 December 2020

PD1 signal transduction pathways in T cells.

1 reference

12 December 2020

PD-L1 is an activation-independent marker of brown adipocytes

1 reference

12 December 2020

Nuclear and Fluorescent Labeled PD-1-Liposome-DOX-64Cu/IRDye800CW Allows Improved Breast Tumor Targeted Imaging and Therapy.

1 reference

12 December 2020

Synthesis and Biological Evaluation of a Novel (18)F-labeled Adnectin as a PET Radioligand for Imaging PD-L1 Expression.

1 reference

12 December 2020

Imaging PD-L1 Expression with ImmunoPET.

1 reference

12 December 2020

Improved resection and prolonged overall survival with PD-1-IRDye800CW fluorescence probe-guided surgery and PD-1 adjuvant immunotherapy in 4T1 mouse model.

1 reference

12 December 2020

Tumor Mutational Burden and Response Rate to PD-1 Inhibition.

1 reference

12 December 2020

Dosimetry Prediction for Clinical Translation of 64Cu-Pembrolizumab ImmunoPET Targeting Human PD-1 Expression.

1 reference

12 December 2020

PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression.

1 reference

12 December 2020

Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma.

1 reference

12 December 2020

Identifiers

DOI

10.7150/THNO.24762

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30026866%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30026866%20AND%20SRC:MED&resulttype=core&format=json

13 April 2020

1 reference